CL2014003455A1 - Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos. - Google Patents

Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.

Info

Publication number
CL2014003455A1
CL2014003455A1 CL2014003455A CL2014003455A CL2014003455A1 CL 2014003455 A1 CL2014003455 A1 CL 2014003455A1 CL 2014003455 A CL2014003455 A CL 2014003455A CL 2014003455 A CL2014003455 A CL 2014003455A CL 2014003455 A1 CL2014003455 A1 CL 2014003455A1
Authority
CL
Chile
Prior art keywords
masp
disorders
treatment
optionally
various diseases
Prior art date
Application number
CL2014003455A
Other languages
English (en)
Inventor
Gregory A Demopulos
Hans Wilhelm Schwaeble
Thomas Dudler
Patrick Gray
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49769678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003455(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of CL2014003455A1 publication Critical patent/CL2014003455A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
CL2014003455A 2012-06-18 2014-12-18 Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos. CL2014003455A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661167P 2012-06-18 2012-06-18

Publications (1)

Publication Number Publication Date
CL2014003455A1 true CL2014003455A1 (es) 2015-04-10

Family

ID=49769678

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014003455A CL2014003455A1 (es) 2012-06-18 2014-12-18 Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.
CL2016003297A CL2016003297A1 (es) 2012-06-18 2016-12-22 Composiciones y métodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de diversas enfermedades y trastornos. (divisional solicitud 3455-2014)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2016003297A CL2016003297A1 (es) 2012-06-18 2016-12-22 Composiciones y métodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de diversas enfermedades y trastornos. (divisional solicitud 3455-2014)

Country Status (26)

Country Link
US (6) US20130344073A1 (es)
EP (5) EP2861246B1 (es)
JP (6) JP6445972B2 (es)
KR (4) KR102339315B1 (es)
CN (4) CN104717975A (es)
AU (3) AU2013277309B2 (es)
BR (1) BR112014031522A2 (es)
CA (2) CA2875567C (es)
CL (2) CL2014003455A1 (es)
CY (1) CY1124234T1 (es)
DK (1) DK2861246T3 (es)
ES (1) ES2864857T3 (es)
HR (1) HRP20210559T1 (es)
HU (1) HUE053727T2 (es)
IL (2) IL236327B (es)
IN (1) IN2015KN00015A (es)
LT (1) LT2861246T (es)
MX (4) MX381048B (es)
NZ (1) NZ629473A (es)
PL (1) PL2861246T3 (es)
PT (1) PT2861246T (es)
RS (1) RS61755B1 (es)
RU (2) RU2019140356A (es)
SI (1) SI2861246T1 (es)
WO (1) WO2013192240A2 (es)
ZA (1) ZA201500094B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CN107638565B (zh) 2011-04-08 2021-12-21 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的状况的方法
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
US9217042B2 (en) * 2012-10-23 2015-12-22 Abbott Cardiovascular Systems Inc. Method of reducing MACE in diabetic patients subsequent to stent placement
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
AU2014229020B2 (en) 2013-03-15 2017-09-28 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
WO2014169076A1 (en) * 2013-04-09 2014-10-16 Annexon,,Inc. Methods of treatment for neuromyelitis optica
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
US20170209549A1 (en) * 2014-06-05 2017-07-27 The Regents Of The University Of Colorado, A Body Corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
ES3013108T3 (en) 2014-11-05 2025-04-11 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
CA2987976A1 (en) * 2015-06-03 2016-12-08 Coyne Ip Holdings, Llc Methods for establishing threshold limits for a chemical or biological agent in a target species
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EA201891132A1 (ru) * 2015-11-09 2018-10-31 Омерос Корпорейшн Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента
CN115260310B (zh) 2015-11-24 2025-02-25 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
SG11201805695SA (en) * 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
EA202191185A1 (ru) * 2016-03-31 2021-10-29 Омерос Корпорейшн Способы ингибирования ангиогенеза у пациента
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
JP7409871B2 (ja) * 2017-04-03 2024-01-09 中外製薬株式会社 抗ｍａｓｐ－１抗体およびその使用方法
BR112020003632A2 (pt) * 2017-08-25 2020-10-27 Omeros Corporation método de tratamento de um indivíduo que sofre ou corre risco de desenvolver ahus
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
CN120209132A (zh) * 2018-04-13 2025-06-27 中外制药株式会社 抗补体组分抗体及使用方法
CN118373875A (zh) 2018-05-29 2024-07-23 奥默罗斯公司 Masp-2抑制剂和使用方法
JP2021527698A (ja) * 2018-06-22 2021-10-14 オメロス コーポレーション 様々な血栓性の疾患および障害の治療のためのｍａｓｐ−２を阻害する組成物および方法
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3856164B1 (en) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
BR112021011727A2 (pt) 2018-12-17 2021-08-31 Achillion Pharmaceuticals, Inc Dosagem direcionada para o tratamento de distúrbios mediados do complemento
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
CN114585637B (zh) 2019-05-07 2025-04-15 拜耳公司 Masp抑制化合物及其用途
CN114096562B (zh) 2019-05-15 2025-02-21 中外制药株式会社 抗原结合分子、药物组合物和方法
US20240109957A1 (en) * 2019-10-17 2024-04-04 Annexon, Inc. Compositions and methods for treating blood disorders
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
WO2021113682A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
KR20220110531A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
KR20220110529A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
CN112237630A (zh) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
TWI867422B (zh) * 2020-03-06 2024-12-21 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
BR112023002843A2 (pt) 2020-08-18 2023-03-14 Omeros Corp Anticorpo isolado ou fragmento de ligação a antígeno do mesmo, molécula de ácido nucleico, vetor de clonagem ou cassete de expressão, célula, métodos para gerar um anticorpo isolado ou fragmento de ligação a antígeno do mesmo, para determinar a presença ou quantidade de fator d maduro e de pró-fator d em uma amostra de teste, para avaliar o grau de ativação do caminho alternativo de complemento (apc) em uma amostra de teste, para monitorar a eficácia de tratamento com um anticorpo inibidor de lectina serina protease 3 de ligação a manana ou fragmento de ligação a antígeno do mesmo e para tratar um sujeito mamífero sofrendo de ou em risco de desenvolver uma doença ou distúrbio do caminho alternativo, composição, substrato para o uso em um imunoensaio, kit para detectar a presença ou quantidade de fator d maduro em uma amostra de teste, composição farmacêutica, e, artigo de fabricação
CN115215937B (zh) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
PY22106817A (es) 2021-12-10 2023-12-21 Omeros Corp Anticuerpos terapéuticos que se unen al dominio serina-proteasa de masp-2 y usos de estos
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
CN114989259B (zh) * 2022-05-27 2023-06-09 成都佩德生物医药有限公司 一种小分子肽Ped4及应用
CN115125299A (zh) * 2022-08-09 2022-09-30 大连珍奥药业股份有限公司 Masp1在筛选预防和/或治疗心血管疾病的药物中的应用
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Ｍａｓｐ－２阻害物質としての縮合ピリミジン
WO2024186766A1 (en) * 2023-03-03 2024-09-12 The City University Of New York Use of extracellular vesicles as biomarkers for age-related macular degeneration
WO2025076476A2 (en) 2023-10-06 2025-04-10 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US20030186419A1 (en) * 1999-12-02 2003-10-02 Jensenius Jens Christian Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
PT1344533E (pt) * 2002-03-15 2007-01-31 Natimmune As Composições farmacêuticas compreendendo lectina de ligação a manose
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
EP1601377A4 (en) * 2003-02-21 2009-07-15 Genentech Inc METHOD FOR THE PREVENTION AND TREATMENT OF TISSUE DAMAGE IN CONNECTION WITH ISCHEMIC REPERFUSION DAMAGE
ES2360399T3 (es) * 2003-07-08 2011-06-03 Umc Utrecht Holding B.V. Uso terapéutico de lpi, un inhibidor de la vía de las lectinas de origen estafilocócico, en enfermedades inflamatorias.
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2386315A1 (en) * 2004-06-10 2011-11-16 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN100518905C (zh) * 2004-11-02 2009-07-29 浙江欧美环境工程有限公司 折返式电除盐器
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
MX2008004693A (es) * 2005-10-21 2008-09-03 Catalyst Biosciences Inc Proteasas modificadas que inhiben la activacion del complemento.
EP2596807B1 (en) * 2006-03-08 2015-12-16 Archemix LLC Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
CA2685714C (en) 2007-05-31 2016-04-12 University Of Washington Inducible mutagenesis of target genes
US9447176B2 (en) * 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
KR20120105405A (ko) * 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
WO2011006982A2 (en) * 2009-07-17 2011-01-20 Rigshospitalet Inhibitors of complement activation
AU2010306581B2 (en) * 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US9815876B2 (en) * 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
CN107638565B (zh) * 2011-04-08 2021-12-21 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的状况的方法
SMT201800253T1 (it) * 2012-04-06 2018-07-17 Omeros Corp Composizioni e metodi per inibire masp-1 e/o masp-3 per il trattamento di emoglobinuria parossistica notturna
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة

Also Published As

Publication number Publication date
HRP20210559T1 (hr) 2021-05-14
US20260049158A1 (en) 2026-02-19
JP2024099699A (ja) 2024-07-25
JP7839502B2 (ja) 2026-04-02
AU2013277309B2 (en) 2018-03-29
JP2021006546A (ja) 2021-01-21
AU2020202999B2 (en) 2022-03-24
EP3878865A3 (en) 2021-12-08
CN109908352A (zh) 2019-06-21
CA3214532A1 (en) 2013-12-27
CY1124234T1 (el) 2022-05-27
US20240254257A1 (en) 2024-08-01
EP2861246A4 (en) 2016-03-23
US20260035483A1 (en) 2026-02-05
KR20200116164A (ko) 2020-10-08
IL236327B (en) 2019-02-28
RU2019140356A (ru) 2020-01-27
CN104717975A (zh) 2015-06-17
LT2861246T (lt) 2021-04-26
JP6445972B2 (ja) 2018-12-26
BR112014031522A2 (pt) 2017-08-01
JP6771531B2 (ja) 2020-10-21
MX2020005700A (es) 2020-09-25
EP4659763A2 (en) 2025-12-10
MX381048B (es) 2025-04-01
KR20200015952A (ko) 2020-02-13
AU2018204285B2 (en) 2020-02-27
EP2861246A2 (en) 2015-04-22
US20190127484A1 (en) 2019-05-02
CA2875567C (en) 2023-11-14
NZ728179A (en) 2021-12-24
RU2015101230A (ru) 2016-08-10
EP4659763A3 (en) 2025-12-24
AU2013277309A1 (en) 2015-01-22
CA2875567A1 (en) 2013-12-27
EP4119577A2 (en) 2023-01-18
AU2020202999A1 (en) 2020-05-28
NZ629473A (en) 2017-02-24
WO2013192240A2 (en) 2013-12-27
IL261436A (en) 2018-11-04
JP2026021601A (ja) 2026-02-10
KR20220100997A (ko) 2022-07-18
US20220259325A1 (en) 2022-08-18
EP3058951A1 (en) 2016-08-24
CL2016003297A1 (es) 2017-06-02
SI2861246T1 (sl) 2021-08-31
MX2014015715A (es) 2016-02-05
ZA201500094B (en) 2019-08-28
EP4119577A3 (en) 2023-11-08
IN2015KN00015A (es) 2015-07-31
RU2709351C2 (ru) 2019-12-17
JP2015521623A (ja) 2015-07-30
PT2861246T (pt) 2021-04-05
HK1209623A1 (zh) 2016-04-08
MX2019012909A (es) 2020-12-10
HUE053727T2 (hu) 2021-07-28
IL261436B (en) 2021-08-31
MX2024005899A (es) 2024-05-30
RS61755B1 (sr) 2021-05-31
KR102339315B1 (ko) 2021-12-15
KR20150031298A (ko) 2015-03-23
US20130344073A1 (en) 2013-12-26
EP3878865A2 (en) 2021-09-15
CN118924900A (zh) 2024-11-12
PL2861246T3 (pl) 2021-10-25
EP2861246B1 (en) 2021-01-20
DK2861246T3 (en) 2021-04-26
JP2019048881A (ja) 2019-03-28
WO2013192240A3 (en) 2014-07-03
IL236327A0 (en) 2015-02-26
JP2022084946A (ja) 2022-06-07
ES2864857T3 (es) 2021-10-14
CN115040653A (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
CL2015000873A1 (es) Métodos para el tratamiento del síndrome de alport.
IL256166B (en) Compounds for use in treating neuromuscular disorders
EP3122414A4 (en) Venous disease treatment
PL3157511T3 (pl) Zastosowanie kannabinoidów w leczeniu padaczki
PT4000608T (pt) Composição farmacêutica, métodos para o tratamento e suas utilizações
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
LT3139925T (lt) Valbenazino dozavimo režimas, skirtas gydyti hiperkinetinio judėjimo sutrikimus
SMT201900176T1 (it) Terapia con mrna per il trattamento di malattie oculari
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
HUE053727T2 (hu) MASP-1 és/vagy MASP-2 és/vagy MASP-3 gátlására szolgáló készítmények és eljárások különbözõ betegségek és rendellenességek kezelésére
HUE059303T2 (hu) Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
LT3292875T (lt) Kompozicijos ir būdai, skirti ligų gydymui
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
IL247354A0 (en) Treatment of conditions associated with hyperinsulinaemia
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
BR112017002318A2 (pt) combinações de fármacos para tratar mieloma múltiplo.
LT2961426T (lt) Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
HUE051295T2 (hu) Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
DK3307277T3 (da) Enkeltstrengede oligonukleotider til anvendelse i medicinsk behandling af hudlidelser